Compare Amphastar Pharmaceuticals Inc (AMPH) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MakeMyTrip Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.87 (market cap $868.62M), while MakeMyTrip Ltd trades at $60.15 (market cap $5.78B). The key difference: MakeMyTrip Ltd is far larger — about 6.7× Amphastar Pharmaceuticals Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MMYT | |
|---|---|---|
Market Cap | $868.62M | $5.78B |
Sector | Health | Technology |
52-Week High | $30.81 | $103.21 |
52-Week Low | $16.87 | $36.30 |
Enterprise Value | $1.27B | $6.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
MakeMyTrip (MMYT) trades at $60.70, down 0.34% with a bullish technical signal supported by moving averages. The company reported strong Q1 2027 earnings with revenue growth in hotels and packages offsetting air-ticketing softness. Analysts maintain a 72.7% buy rating with a 34.1% upside target. Recent financials show $978M revenue and $95M net income for 2025, though 2026 projections indicate margin compression.
The stock presents growth potential driven by travel recovery and platform diversification, but faces risks from geopolitical disruptions, fuel costs, and rising debt levels. Current valuation metrics (P/E 267, P/S 6.07) suggest premium pricing requiring sustained execution. Institutional sentiment remains positive despite recent selling by Boston Common Asset Management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
